Major declines in the risk of disease progression and death in people with metastatic melanoma was reported as the effect of a targeted combination drug therapy. A world-first study in today's iNew England Journal of Medicine/i heralds the efficacy of this targeted combination drug therapy. The multi-centre, double-blind, randomized, phase 3 trial compared oral dabrafenib (150 mg twice daily) and oral trametinib (2 mg once daily) combination therapy with oral ...
Read MoreYou have just read an article categorized health
titled Life Extended in Advance Melanoma Patients With Targeted Combination Therapy.
Written by:
editor - Tuesday, September 30, 2014
There are currently no comments for "Life Extended in Advance Melanoma Patients With Targeted Combination Therapy"
Post a Comment